Curated News
By: NewsRamp Editorial Staff
November 14, 2024
Hagens Berman Urges Edwards Lifesciences Corporation (NYSE: EW) Investors Who Suffered Substantial Losses to Submit Their Losses Now
Discuss on Reddit
TelegramTLDR
- Investors who suffered losses urged to submit now for potential recovery.
- The investigation focuses on Edwards Lifesciences' TAVR disclosures and financial results.
- Seeking accountability for potential misleading of investors and harm to shareholder value.
- The continued growth and expansion of heart therapies impacted TAVR sales and stock value.
Impact - Why it Matters
This news matters as it highlights a class action lawsuit against Edwards Lifesciences Corporation for allegedly misleading investors about the true business and growth prospects for TAVR, impacting shareholder value and investor trust.
Summary
Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit their losses now. The class action lawsuit is focused on the propriety of Edwards Lifesciences’ disclosures about its core product, the Transcatheter Aortic Valve Replacement (“TAVR”) platform. Investors learned the truth on July 24, 2024, when Edwards Lifesciences announced its Q2 2024 financial results, revealing that its TAVR sales grew just 5% and slashed its TAVR growth guidance to 5 to 7% from 8 to 10%.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Hagens Berman Urges Edwards Lifesciences Corporation (NYSE: EW) Investors Who Suffered Substantial Losses to Submit Their Losses Now
